MEN1 mutations mediate clinical resistance to menin inhibition.

Animals Humans Antineoplastic Agents / chemistry Binding Sites / drug effects Chromatin / genetics Drug Resistance, Neoplasm / genetics Leukemia / drug therapy Mutation Protein Binding / drug effects Proto-Oncogene Proteins / antagonists & inhibitors

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
03 2023
Historique:
received: 07 03 2022
accepted: 24 01 2023
medline: 31 3 2023
pubmed: 17 3 2023
entrez: 16 3 2023
Statut: ppublish

Résumé

Chromatin-binding proteins are critical regulators of cell state in haematopoiesis

Identifiants

DOI: 10.1038/s41586-023-05755-9 PMID: 36922589 PMC: PMC10157896
pubmed: 36922589
doi: 10.1038/s41586-023-05755-9
pii: 10.1038/s41586-023-05755-9
pmc: PMC10157896
mid: NIHMS1892649
doi:

Substances chimiques

Antineoplastic Agents 0
Chromatin 0
KMT2A protein, human 0
MEN1 protein, human 0
NPM1 protein, human 0
Proto-Oncogene Proteins 0

Types de publication

Clinical Trial, Phase I Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

913-919

Subventions

Organisme : NCI NIH HHS
ID : K08 CA241371
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA176745
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA206963
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204639
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA066996
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197594
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA173636
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM121505
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214608
Pays : United States
Organisme : NCI NIH HHS
ID : CA066966
Pays : United States
Organisme : NCI NIH HHS
ID : F32CA250240-02
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Rodrigues, C. P., Shvedunova, M. & Akhtar, A. Epigenetic regulators as the gatekeepers of hematopoiesis. Trends Genet. 37, P125–P142 (2021).
doi: 10.1016/j.tig.2020.09.015
Uckelmann, H. J. & Armstrong, S. A. Chromatin complexes maintain self-renewal of myeloid progenitors in AML: opportunities for therapeutic intervention. Stem Cell Rep. 15, 6–12 (2020).
doi: 10.1016/j.stemcr.2020.05.013
Yokoyama, A. et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123, 207–218 (2005).
doi: 10.1016/j.cell.2005.09.025 pubmed: 16239140
Yokoyama, A. & Cleary, M. L. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 14, 36–46 (2008).
doi: 10.1016/j.ccr.2008.05.003 pubmed: 18598942 pmcid: 2692591
Kuhn, M. W. et al. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. Cancer Discov. 6, 1166–1181 (2016).
doi: 10.1158/2159-8290.CD-16-0237 pubmed: 27535106 pmcid: 5584808
Issa, G. C. et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature https://doi.org/10.1038/s41586-023-05812-3 (2023).
Huang, J. et al. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 482, 542–546 (2012).
doi: 10.1038/nature10806 pubmed: 22327296 pmcid: 3983792
Hughes, C. M. et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol. Cell 13, 587–597 (2004).
doi: 10.1016/S1097-2765(04)00081-4 pubmed: 14992727
Borkin, D. et al. Pharmacologic inhibition of the menin–MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell 27, 589–602 (2015).
doi: 10.1016/j.ccell.2015.02.016 pubmed: 25817203 pmcid: 4415852
Klossowski, S. et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J. Clin. Invest. 130, 981–997 (2020).
doi: 10.1172/JCI129126 pubmed: 31855575 pmcid: 6994154
Lei, H. et al. Recent progress of small molecule menin–MLL interaction inhibitors as therapeutic agents for acute leukemia. J. Med. Chem. 64, 15519–15533 (2021).
doi: 10.1021/acs.jmedchem.1c00872 pubmed: 34726905
Perner, F. & Armstrong, S. A. Targeting chromatin complexes in myeloid malignancies and beyond: from basic mechanisms to clinical innovation. Cells 9, 2721 (2020).
doi: 10.3390/cells9122721 pubmed: 33371192 pmcid: 7767226
Uckelmann, H. J. et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science 367, 586–590 (2020).
doi: 10.1126/science.aax5863 pubmed: 32001657 pmcid: 7754791
Krivtsov, A. V. et al. A menin–MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell 36, 660–673.e11 (2019).
doi: 10.1016/j.ccell.2019.11.001 pubmed: 31821784 pmcid: 7227117
Lemos, M. C. & Thakker, R. V. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat. 29, 22–32 (2008).
doi: 10.1002/humu.20605 pubmed: 17879353
Hanna, R. E. et al. Massively parallel assessment of human variants with base editor screens. Cell 184, 1064–1080.e20 (2021).
doi: 10.1016/j.cell.2021.01.012 pubmed: 33606977
Zimmerman, M. I. et al. SARS-CoV-2 simulations go exascale to predict dramatic spike opening and cryptic pockets across the proteome. Nat. Chem. 13, 651–659 (2021).
doi: 10.1038/s41557-021-00707-0 pubmed: 34031561 pmcid: 8249329
Ward, M. D. et al. Deep learning the structural determinants of protein biochemical properties by comparing structural ensembles with DiffNets. Nat. Commun. 12, 3023 (2021).
doi: 10.1038/s41467-021-23246-1 pubmed: 34021153 pmcid: 8140102
Sun, X., Singh, S., Blumer, K. J. & Bowman, G. R. Simulation of spontaneous G protein activation reveals a new intermediate driving GDP unbinding. eLife 7, e38465 (2018).
doi: 10.7554/eLife.38465 pubmed: 30289386 pmcid: 6224197
Grembecka, J., Belcher, A. M., Hartley, T. & Cierpicki, T. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias. J. Biol. Chem. 285, 40690–40698 (2010).
doi: 10.1074/jbc.M110.172783 pubmed: 20961854 pmcid: 3003368
Bai, H. et al. Menin–MLL protein–protein interaction inhibitors: a patent review (2014–2021). Expert Opin. Ther. Pat. 32, 507–522 (2022).
doi: 10.1080/13543776.2022.2045947 pubmed: 35202550
Ross, D. S. et al. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Mod. Pathol. 32, 81–87 (2019).
doi: 10.1038/s41379-018-0116-5 pubmed: 30158597
Biancaniello, C. et al. Investigating the effects of amino acid variations in human menin.Molecules 27, 1747 (2022).
doi: 10.3390/molecules27051747 pubmed: 35268848 pmcid: 8911756
Nikolovska-Coleska, Z. et al. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal. Biochem. 332, 261–273 (2004).
doi: 10.1016/j.ab.2004.05.055 pubmed: 15325294
Shi, A. et al. Structural insights into inhibition of the bivalent menin–MLL interaction by small molecules in leukemia. Blood 120, 4461–4469 (2012).
doi: 10.1182/blood-2012-05-429274 pubmed: 22936661 pmcid: 3512226
Olsen, S. N. et al. MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape. Mol. Cell 82, 1140–1155.e1111 (2022).

Auteurs

Florian Perner (F)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Internal Medicine C, University Medicine Greifswald, Greifswald, Germany.

Eytan M Stein (EM)

Leukemia Service, Department of Medicine, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Daniela V Wenge (DV)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0002-0064-9104

Sukrit Singh (S)

Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Jeonghyeon Kim (J)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

Athina Apazidis (A)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.

Homa Rahnamoun (H)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0002-0555-2328

Disha Anand (D)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Internal Medicine C, University Medicine Greifswald, Greifswald, Germany.

Christian Marinaccio (C)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.

Charlie Hatton (C)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.

Yanhe Wen (Y)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.

Richard M Stone (RM)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
ORCID: 0000-0002-7526-2633

David Schaller (D)

In silico Toxicology and Structural Bioinformatics, Institute of Physiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Shoron Mowla (S)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Wenbin Xiao (W)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0001-8586-8500

Holly A Gamlen (HA)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0002-3746-2909

Aaron J Stonestrom (AJ)

Leukemia Service, Department of Medicine, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0002-0602-1158

Sonali Persaud (S)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Elizabeth Ener (E)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0002-4147-1146

Jevon A Cutler (JA)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.

John G Doench (JG)

Genetic Perturbation Platform, Broad Institute, Cambridge, MA, USA.
ORCID: 0000-0002-3707-9889

Gerard M McGeehan (GM)

Syndax Pharmaceuticals, Waltham, MA, USA.

Andrea Volkamer (A)

In silico Toxicology and Structural Bioinformatics, Institute of Physiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

John D Chodera (JD)

Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0003-0542-119X

Radosław P Nowak (RP)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

Eric S Fischer (ES)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0001-7337-6306

Ross L Levine (RL)

Leukemia Service, Department of Medicine, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. leviner@mskcc.org.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. leviner@mskcc.org.
ORCID: 0000-0002-7884-1905

Scott A Armstrong (SA)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA. scott_armstrong@dfci.harvard.edu.
ORCID: 0000-0002-9099-4728

Sheng F Cai (SF)

Leukemia Service, Department of Medicine, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. cais1@mskcc.org.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. cais1@mskcc.org.
ORCID: 0000-0002-2708-887X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › MEN1 mutations mediate clinical resistance to...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › MEN1 mutations mediate clinical resistance to...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › MEN1 mutations mediate clinical resistance to...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Sites de fixation › MEN1 mutations mediate clinical resistance to...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Structures de chromosome › Chromatine › MEN1 mutations mediate clinical resistance to...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › MEN1 mutations mediate clinical resistance to...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › MEN1 mutations mediate clinical resistance to...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › MEN1 mutations mediate clinical resistance to...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › MEN1 mutations mediate clinical resistance to...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › MEN1 mutations mediate clinical resistance to...